A multicenter, randomized, double blind, placebo-controlled, phase 3 study to evaluate cardiovascular outcomes of TAK-875, 50 mg - Bronson Healthcare

Diabetes Type 2

A multicenter, randomized, double blind, placebo-controlled, phase 3 study to evaluate cardiovascular outcomes of TAK-875, 50 mg in addition to standard of care in subjects with Type 2 diabetes and with cardiovascular disease or multiple risk factors for cardiovascular events.

Objective

The purpose of this study is to evaluate the risk of cardiovascular events in high risk patients with Type 2 diabetes mellitus when they are treated with TAK-875 as compared with placebo. Patients who are eligible for this study must have had a heart attack within the past two years, or have peripheral vascular disease, or have had a stroke or TIA within the past two years.

ClinicalTrials.Gov Number
NCT01609582
Principal Investigator(s)
Christopher Rogers, DO
Sponsor(s)
Takeda Global Research & Development Center
Contact
Gail Massey, RN, BS at 269-341-8774
or masseyg@bronsonhg.com
How to Participate
Subjects will receive their usual care for their diabetes and will be randomly assigned to receive either a placebo or TAK-875 in addition. The study will last for up to 6 years and will enroll 5000 patients.
More information can be found here.

Location

  • Bronson Advanced Cardiac Healthcare - Kalamazoo
    601 John St.
    Suite 100
    Kalamazoo, MI 49007
    Main: 269-373-1222
    Alternate: 800-483-8333
    Fax: 269-373-6270